Every week, Seeking Alpha aggregates expected biotech events in an effort to alert readers and contributors to upcoming catalysts. Crowdsourcing is key, so please let us know about any events we may have missed. Have a view on something that's ... Seeking Alpha, 1 day ago
3 images for "pdufa"
Are you Bullish or Bearish on ? Bullish Bearish Neutral Results for ( ) Bullish Bearish Neutral Thanks for sharing your thoughts. Submit & View Results Skip toSeeking Alpha, 2 weeks ago
FDA Accepts BLA Filing For Synageva's Kanuma (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date
LEXINGTON, Mass. , Feb. 23, 2015 /PRNewswire/ -- Synageva BioPharma Corp. ( NASDAQ: GEVA ), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted ...Franklin Credit Management Corporation, 5 days ago Press Release: FDA Accepts BLA Filing For Synageva's Kanuma(TM) (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date iMarketReports, 5 days ago Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma Morningstar.com, 1 week ago Synageva BioPharma Reports 2014 Full Year Financial Results TickerTech.com, 1 day ago
--(PR.com)-- Immune Response BioPharma, Inc., today announces receipt of Remune FDA BLA Assignment PDUFA goal date of December 22nd 2015 for Therapeutic HIV/AIDS Vaccine. The FDA previously granted Remune FDA Pediatric Orphan Designation in ...BioSpace, 1 week ago
Multimedia Assets Now Available: FDA Approves Eisai's LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer
• Approval Granted Two Months Ahead of FDA Priority Review PDUFA Date Woodcliff Lake, NJ February 13, 2015 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine ...BioMedReports, 2 weeks ago D.C. Week: Harmony at Vaccine Hearing, Thyroid Ca Drug OK'd MedPage Today, 2 weeks ago FDA Approves Eisai's LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Reuters, 2 weeks ago FDA Approves Thyroid Cancer Drug Early MedPage Today, 2 weeks ago
More from: , WSPA...and 2 other sources
OPKO Health, Inc. ( NYSE:OPK ) , a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its fourth quarter ended December 31, 2014. Business Highlights Pfizer Collaboration ...Minyanville, 21 hours ago OPKO HEALTH : Announces Fourth Quarter Operating and Financial Results 4 Traders, 21 hours ago TESARO Announces Fourth-Quarter 2014 Operating Results BioSpace, 1 week ago TESARO : Announces Fourth-Quarter 2014 Operating Results 4 Traders, 1 week ago
Bristol-Myers Squibb Company BMY, -0.50% today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics Licensing Application (BLA) for Opdivo(nivolumab)for the treatment of patients with advanced ...American Journal of Managed Care, 23 hours ago U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer SearchBug, 1 day ago U.S. Food & Drug Administration Accepts Biologics Licensing.. ADVFN Australia, 1 day ago BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer 4 Traders, 1 day ago
Pacira Pharmaceuticals provided updates on the success of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended ...4 Traders, 14 hours ago Pacira Pharmaceuticals Posts 2014 Financial Results Individual.com, 1 day ago Pacira Pharmaceuticals' (PCRX) CEO Dave Stack on Q4 2014 Results - Earnings Call Transcript Seeking Alpha, 3 days ago Pacira Pharma Swings To Profit In Q4 - Quick Facts RTTNews.com, 4 days ago
Feb. 27, 2015 9:35 PM ET | About: Gilead Sciences, Inc. (GILD) by: Gilead Sciences, Inc. (NASDAQ:GILD) RBC Healthcare Conference Call Executives Sung Lee - IR Robin Washington - EVP and CFO Analysts Michael Yee - RBC Capital Markets ...Seeking Alpha, 17 hours ago
FDA Advisory Committee Recommends Approval for Avedro's Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia
Avedro, Inc., a Boston-based ophthalmic pharmaceutical and medical device company, announced today that on February 24, 2015 the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee and ...RCL Advisors, 1 day ago Avedro Announces Date for FDA Advisory Committee Meeting EON: Enhanced Online News, 1 week ago Avedro Sets Date for FDA Advisory Committee Meeting Individual.com, 1 week ago Avedro, Inc. Announces Date For FDA Advisory Committee Meeting BioSpace, 1 week ago
on your WebpageAdd Widget >Get your members hooked!